-
Pfizer submits application to FDA for Sutent (SU11248)
NEW YORK, August 10 — Pfizer Inc said today that it has submitted aNew Drug Application for its cancer medicine SU11248 (sunitinibmalate), known as Sutent, to the U.S. Food and Drug Administration. Pfizeris seeking FDA approval for Sutent as a treatment for malignantgastrointestinal stromal tumor and metastatic renal cell carcinomaamong patients whose tumors do not […]
Continue reading -
ECCO 13 – Sunitinib prolongs survival in GIST patients after imatinib mesylate failure
Paris, France, Thursday 3 November 2005 – Updated results from a PhaseIII trial presented at the 13th European Cancer Conference (ECCO) showthat sunitinib (SU11248) prolongs both progression-free and overallsurvival in patients with progressive metastatic and/or unresectableGIST whose disease has failed to respond to the standard therapy -imatinib mesylate. This study was a double-blind, placebo-controlled, international,multicentre, […]
Continue reading -
Various Shades of Depression
"Various shades of depression are often par for the course with cancer, and can affect patients as well as close family members both directly and indirectly. There are various types and degrees of clinical depression, each requiring individual evaluation and appropriate treatment. Depression can also be an understandable and realistic reaction to cancer, and to […]
Continue reading -
Anger and Resentment
Among the many posts to this List, we can sometimes hear the shouts and murmurs of our mingled voices – and some of the human sounds of our GISTmates. As we have come to share among ourselves something of our individual circumstances and personal worries, we have grown closer together – and I believe, at […]
Continue reading